{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:26:42Z","timestamp":1772166402421,"version":"3.50.1"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,17]],"date-time":"2020-01-17T00:00:00Z","timestamp":1579219200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,1,17]],"date-time":"2020-01-17T00:00:00Z","timestamp":1579219200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Antimicrobial therapy with appropriate biliary drainage is considered the standard of care for acute cholangitis, but the optimal duration of antimicrobial therapy remains unknown. Seven to 10\u2009days of antimicrobial therapy are common for the treatment of acute cholangitis, but a recent retrospective cohort study suggested a shorter duration might be effective. A shorter duration of antimicrobial therapy can be beneficial in decreasing the length of hospital stay, improving patients\u2019 quality of life, decreasing adverse effects, and even contributing to a decrease in the occurrence of antimicrobial resistance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods\/design<\/jats:title>\n                    <jats:p>We will conduct a multi-centre, open-label, randomized, non-inferiority trial to compare short-course therapy (SCT) with conventional long-course therapy (LCT) in treating patients with acute cholangitis. SCT consists of 5-day intravenous antimicrobial therapy if the patients had clinical improvement, while at least 7\u2009days of intravenous antibiotics will be provided to the LCT group. The primary outcome is clinical cure at 30\u2009days after onset. Patients will be randomly assigned in an open-label fashion. A total sample size of 150 was estimated to provide a power of 80% with a one-sided \u03b1 level of 2.5% and a non-inferiority margin of 10%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This trial is expected to reveal whether SCT is non-inferior to conventional LCT or not, and may provide evidence that one can shorten the treatment duration for acute cholangitis for the benefit of patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      University Hospital Medical Information Network,\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/upload.umin.ac.jp\/cgi-open-bin\/ctr_e\/ctr_view.cgi?recptno=R000032491\">UMIN000028382<\/jats:ext-link>\n                      . Registered on 30 August 2017.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13063-020-4046-4","type":"journal-article","created":{"date-parts":[[2020,1,17]],"date-time":"2020-01-17T08:02:23Z","timestamp":1579248143000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Shortening antibiotic duration in the treatment of acute cholangitis: rationale and study protocol for an open-label randomized controlled trial"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2148-3016","authenticated-orcid":false,"given":"Kentaro","family":"Iwata","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asako","family":"Doi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichiro","family":"Oba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroo","family":"Matsuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kei","family":"Ebisawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manabu","family":"Nagata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sho","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Yoshimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsuhiro","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideyuki","family":"Shiomi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuzo","family":"Kodama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,1,17]]},"reference":[{"key":"4046_CR1","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1111\/j.1572-0241.2007.01095.x","volume":"102","author":"C-C Lee","year":"2007","unstructured":"Lee C-C, Chang I-J, Lai Y-C, Chen SY, Chen SC. Epidemiology and prognostic determinants of patients with bacteraemic cholecystitis or cholangitis. Am J Gastroenterol. 2007;102:563\u20139.","journal-title":"Am J Gastroenterol"},{"key":"4046_CR2","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1093\/jac\/dks062","volume":"676","author":"M Ortega","year":"2012","unstructured":"Ortega M, Marco F, Soriano A, Almela M, Martinez JA, L\u00f3pez J, et al. Epidemiology and prognostic determinants of bacteraemic biliary tract infection. J Antimicrob Chemother. 2012;676:1508\u201313.","journal-title":"J Antimicrob Chemother"},{"key":"4046_CR3","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/ajg.2011.387","volume":"107","author":"YK Sung","year":"2012","unstructured":"Sung YK, Lee JK, Lee KH, Lee KT, Kang CI. The clinical epidemiology and outcomes of bacteraemic biliary tract infections caused by antimicrobial-resistant pathogens. Am J Gastroenterol. 2012;107:473\u201383.","journal-title":"Am J Gastroenterol"},{"key":"4046_CR4","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1136\/pgmj.2007.064683","volume":"83","author":"M Melzer","year":"2007","unstructured":"Melzer M, Toner R, Lacey S, Bettany E, Rait G. Biliary tract infection and bacteraemia: presentation, structural abnormalities, causative organisms and clinical outcomes. Postgrad Med J. 2007;83:773\u20136.","journal-title":"Postgrad Med J"},{"key":"4046_CR5","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1136\/gut.25.9.988","volume":"25","author":"JS Dooley","year":"1984","unstructured":"Dooley JS, Hamilton-Miller JM, Brumfitt W, Sherlock S. Antibiotics in the treatment of biliary infection. Gut. 1984;25:988\u201398.","journal-title":"Gut."},{"key":"4046_CR6","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1016\/j.cmi.2018.01.021","volume":"24","author":"A Doi","year":"2018","unstructured":"Doi A, Morimoto T, Iwata K. Shorter duration of antibiotic treatment for acute bacteraemic cholangitis with successful biliary drainage: a retrospective cohort study. Clin Microbiol Infect. 2018;24:1184\u20139.","journal-title":"Clin Microbiol Infect"},{"key":"4046_CR7","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1093\/cid\/cir063","volume":"52","author":"Y Hayashi","year":"2011","unstructured":"Hayashi Y, Paterson DL. Strategies for reduction in duration of antibiotic use in hospitalized patients. Clin Infect Dis. 2011;52:1232\u201340.","journal-title":"Clin Infect Dis"},{"key":"4046_CR8","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1086\/526535","volume":"46","author":"LB Rice","year":"2008","unstructured":"Rice LB. The Maxwell Finland Lecture: for the duration-rational antibiotic administration in an era of antimicrobial resistance and clostridium difficile. Clin Infect Dis. 2008;46:491\u20136.","journal-title":"Clin Infect Dis"},{"key":"4046_CR9","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1097\/CCM.0b013e31821b85f4","volume":"39","author":"MT Johnson","year":"2011","unstructured":"Johnson MT, Reichley R, Hoppe-Bauer J, Dunne WM, Micek S, Kollef M. Impact of previous antibiotic therapy on outcome of Gram-negative severe sepsis. Crit Care Med. 2011;39:1859\u201365.","journal-title":"Crit Care Med"},{"key":"4046_CR10","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1093\/cid\/cir301","volume":"53","author":"V Stevens","year":"2011","unstructured":"Stevens V, Dumyati G, Fine LS, van Wijngaarden E. Cumulative antibiotic exposures over time and the risk of Clostridium difficile infection. Clin Infect Dis. 2011;53:42\u20138.","journal-title":"Clin Infect Dis"},{"key":"4046_CR11","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1001\/jama.2012.87802","volume":"308","author":"G Piaggio","year":"2012","unstructured":"Piaggio G, Elbourne DR, Pocock SJ, Evans SJ, Altman DG, CONSORT Group. Reporting of noninferiority and equivalence randomized trial: extension of the CONSORT 2010 statement. JAMA. 2012;308:2594\u2013604.","journal-title":"JAMA"},{"key":"4046_CR12","doi-asserted-by":"publisher","DOI":"10.1201\/9781315183084","volume-title":"Sample size calculations in clinical research","author":"S-C Chow","year":"2017","unstructured":"Chow S-C, Shao J, Wang H, Lokhnygina Y. Sample size calculations in clinical research. 3rd ed. Boca Raton: Chapman & Hall\/CRC; 2017.","edition":"3"},{"issue":"3","key":"4046_CR13","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1086\/600296","volume":"49","author":"B Spellberg","year":"2009","unstructured":"Spellberg B, Talbot GH, Boucher HW, Bradley JS, Gilbert D, Scheld WM, et al. Antimicrobial agents for complicated skin and skin-structure infections: justification of noninferiority margins in the absence of placebo-controlled trials. Clin Infect Dis. 2009;49(3):383\u201391.","journal-title":"Clin Infect Dis"},{"key":"4046_CR14","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1056\/NEJMoa1411162","volume":"372","author":"RG Sawyer","year":"2015","unstructured":"Sawyer RG, Claridge JA, Nathens AB, Rotstein OD, Duane TM, Evans HL, et al. Trial of short-course antimicrobial therapy for intraabdominal infection. N Engl J Med. 2015;372:1996\u20132005.","journal-title":"N Engl J Med"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-020-4046-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13063-020-4046-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-020-4046-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T19:17:58Z","timestamp":1610738278000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-020-4046-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,17]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["4046"],"URL":"https:\/\/doi.org\/10.1186\/s13063-020-4046-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.12513\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.12513\/v1","asserted-by":"object"}]},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,17]]},"assertion":[{"value":"2 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The protocol and consent forms were approved by the ethics committee at Kobe University Graduate School of Medicine and each of the participating institutions. All substantial protocol modifications will be notified as protocol amendments to these institutions. All patients or their legally authorized representatives will provide written informed consent before randomization by the investigators.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"97"}}